PRE

4 - Prenetics Global Ltd (0001876431) (Issuer)

3/A - Prenetics Global Ltd (0001876431) (Issuer)

4 - Prenetics Global Ltd (0001876431) (Issuer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

Multi-year partnership lands as Prenetics' IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026Shetty is IM8's first global ambassador from outside the world of sport Joins an equity-aligned roster of David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, and Inter Miami CF (with Lionel Messi) NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with #1 New York Times bestselling author and awar

6-K - Prenetics Global Ltd (0001876431) (Filer)

~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced the appointment of Brian J. Rosin as U.S. Chief Financial Officer. Mr. Rosin will be based in the U.S. and will lead the Company's finance organization, reporting to Chief Executive Officer Danny Yeung.   Mr. Rosin's appointment establishes dedicated finance leadership for IM8 to support the Company's growing operations and the rap

6-K - Prenetics Global Ltd (0001876431) (Filer)

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced it will release financial results for the first quarter 2026 ended March 31, 2026 before market open on Thursday, May 14, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Thursday, May 14, 2026Time:8:30 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878WebcastPRE Conference Call

6-K - Prenetics Global Ltd (0001876431) (Filer)

NEW YORK and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year partnership with Inter Miami CF, the Major League Soccer club owned by Jorge Mas, Jose Mas and David Beckham. Under the agreement, IM8 becomes Inter Miami CF's exclusive Official Health Supplements Partner. The partnership also includes an equity stake in Prenetics, marking the first time Inter Miami CF has taken an equity position in a brand partner. The partnership brings David Beckham's two ventures full circle. As co-founder of IM8 and

6-K - Prenetics Global Ltd (0001876431) (Filer)

6-K - Prenetics Global Ltd (0001876431) (Filer)

Giannis becomes the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand, joining the fastest supplement company ever to reach $100M ARR in just 11 months Giannis unlocks 35 million followers across social channels - NBA broadcasted in 215 countries To learn more about Giannis and IM8, please visit www.im8health.com NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with NBA Champion and two-time MVP Giannis Antetokounmpo. Giannis becomes a Global Partner of

F-3 - Prenetics Global Ltd (0001876431) (Filer)

3 - Prenetics Global Ltd (0001876431) (Issuer)

3 - Prenetics Global Ltd (0001876431) (Issuer)

IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols. NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium heal

3 - Prenetics Global Ltd (0001876431) (Issuer)

3 - Prenetics Global Ltd (0001876431) (Issuer)

3 - Prenetics Global Ltd (0001876431) (Issuer)

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the Company will participate in the 38th Annual ROTH Conference being held Sunday, March 22nd to Tuesday, March 24th at the Ritz-Carlton in Laguna Niguel, CA. Prenetics CEO Danny Yeung and President of Americas David Vanderveen will be available for one-on-one meetings throughout the conference. Management will also participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel discussion at 12:00 p.m. PT on Monday, March 23rd — both available via webc

Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

6-K - Prenetics Global Ltd (0001876431) (Filer)

Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027 NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced that its Board of Directors (the "Board") has authorized a share repurchase program of up to $40,000,000 over a 12-month period. Management Voted With Its Own Capital First During the week of Feb